Yuhan Corporation announced on the 11th through a public disclosure that it plans to receive $60 million (approximately 80.4 billion won) in commercialization technology fees for the targeted anticancer drug ‘Lazertinib (Korean product name: Leclaza),’ which was exported to Janssen Biotech, a subsidiary of Johnson & Johnson (J&J) in the United States.
This milestone payment is in response to the start of commercialization of the combination therapy of Yuhan Corporation’s Lazertinib and Janssen Biotech’s dual anticancer antibody ‘Amivantamab’ (product name Librevant).
According to Yuhan Corporation, combination therapy of the two drugs has begun in the United States and the first patient has been administered successfully. Earlier, on the 20th of last month, the U.S. Food and Drug Administration (FDA) approved combination therapy of the two drugs as the first-line treatment for patients with metastatic non-small cell lung cancer.
Lazertinib is a third-generation EGFR mutation-positive non-small cell lung cancer treatment. Combination therapy with amivantamab is attracting attention for patients with resistance such as EGFR mutation and MET amplification.
Yuhan Corporation said that the milestone payment of $60 million is equivalent to approximately 2.5% of the company’s consolidated sales last year (KRW 1.859 trillion). The milestone payment is scheduled to be received within 60 days.
Yuhan Corporation stated, “This achievement is an important milestone that demonstrates the company’s continued global R&D strategy and the development of innovative anticancer treatments,” and “We plan to continue to accelerate the commercialization and additional research and development of Lazertinib combination therapy based on our collaboration with Janssen.”
Hwang So-young, Donga.com reporter [email protected]
-
- great
- 0dog
-
- I’m sad
- 0dog
-
- I’m angry
- 0dog
-
- I recommend it
- dog
Hot news right now
2024-09-11 08:36:38